Literature DB >> 21044440

Side effects and management of side effects of methotrexate in rheumatoid arthritis.

K Albrecht1, U Müller-Ladner.   

Abstract

Low-dose methotrexate (MTX) remains the first-line treatment option among the disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. However, diverse side effects are the major reason for MTX withdrawal and change of treatment. The following article reviews the published data on general and organ-specific side effects and outlines the current recommendations addressing prevention and management of MTX-associated adverse effects.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21044440

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


  23 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis.

Authors:  Elizabeth Pigott; James B DuHadaway; Alexander J Muller; Susan Gilmour; George C Prendergast; Laura Mandik-Nayak
Journal:  Autoimmunity       Date:  2014-05-06       Impact factor: 2.815

3.  Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis.

Authors:  L A Davis; B Polk; A Mann; R K Wolff; G S Kerr; A M Reimold; G W Cannon; T R Mikuls; L Caplan
Journal:  Clin Exp Rheumatol       Date:  2014-01-20       Impact factor: 4.473

4.  Compound GDC, an Isocoumarin Glycoside, Protects against LPS-Induced Inflammation and Potential Mechanisms In Vitro.

Authors:  Yuqin Zhang; Guohong Yan; Chengtao Sun; Lihong Nan; Xiaoying Wang; Wei Xu; Kedan Chu
Journal:  Inflammation       Date:  2019-04       Impact factor: 4.092

5.  Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

Authors:  Lauren M F Merlo; Samantha Grabler; James B DuHadaway; Elizabeth Pigott; Kaylend Manley; George C Prendergast; Lisa D Laury-Kleintop; Laura Mandik-Nayak
Journal:  Clin Immunol       Date:  2017-02-20       Impact factor: 3.969

6.  Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.

Authors:  Dong-Yang Liu; Hoi-Kei Lon; Yan-Lin Wang; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2013-04-07       Impact factor: 1.627

7.  Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.

Authors:  Jeffrey A Sparks; Medha Barbhaiya; Elizabeth W Karlson; Susan Y Ritter; Soumya Raychaudhuri; Cassandra C Corrigan; Fengxin Lu; Jacob Selhub; Daniel I Chasman; Nina P Paynter; Paul M Ridker; Daniel H Solomon
Journal:  Semin Arthritis Rheum       Date:  2017-02-10       Impact factor: 5.532

8.  Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models.

Authors:  Tibor T Glant; Timea Besenyei; András Kádár; Júlia Kurkó; Beata Tryniszewska; János Gál; Györgyi Soós; Zoltán Szekanecz; Gyula Hoffmann; Joel A Block; Robert S Katz; Katalin Mikecz; Tibor A Rauch
Journal:  Arthritis Rheum       Date:  2013-07

9.  Pharmacological evaluation of anti-arthritic potential of terpinen-4-ol using in vitro and in vivo assays.

Authors:  Sania Aslam; Waqas Younis; Muhammad Nasir Hayat Malik; Shah Jahan; Ambreen Malik Uttra; Muhammad Usman Munir; Muhammad Roman
Journal:  Inflammopharmacology       Date:  2022-03-23       Impact factor: 4.473

Review 10.  The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Authors:  Shahin Shams; Joseph M Martinez; John R D Dawson; Juan Flores; Marina Gabriel; Gustavo Garcia; Amanda Guevara; Kaitlin Murray; Noah Pacifici; Maxemiliano V Vargas; Taylor Voelker; Johannes W Hell; Judith F Ashouri
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.